Zymeworks Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Zymeworks announced two major catalysts: (1) U.S. PDUFA decision on zanidatamab for HER2+ gastroesophageal cancer on August 25, 2026, with potential $250M approval milestone plus up to $190M additional global regulatory milestones; (2) pending acquisition of Theravance Biopharma expected to close in 2H 2026, adding YUPELRI (≈$60M annualized cash flow at current run-rate), TRELEGY ELLIPTA royalties, and $2.5B Irish tax attributes, financed by $350M non-recourse note and Theravance's $360M net cash. Q2 2026 revenue declined to $4.6M (from $48.7M in Q2 2025) due to absence of non-recurring collaboration revenue; net loss $45M (vs. $2.3M net income in Q2 2025); cash position $322.5M as of June 30, 2026. Share repurchase program: $49.4M utilized of $125M authorized program through August 4, 2026, acquiring 1,971,454 shares at $25.04/share average.
Why this rating
Transformational deal (11% of market cap) plus regulatory catalyst (≈38% of cap if hit); material revenue diversification and cash flow improvement expected.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.